Karyopharm will host a conference call today, Monday, June 22, 2020, at 12:30 p.m. Eastern Time, to discuss the FDA’s approval of XPOVIO for the treatment of patients with relapsed or refractory DLBCL ...

What the New Price Target Tells You About Karyopharm Therapeutics Karyopharm Therapeutics is back in focus after analysts revised their price target, signaling a meaningful shift in how the market is ...

Karyopharm Therapeutics ( (KPTI)) has issued an update. Karyopharm Therapeutics announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer, and Treasurer, ...

NEWTON, Mass., Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company ...

NEWTON, Mass., Oct. 27, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report ...

– Pivotal Phase 3 Study of Selinexor and Ruxolitinib in Treatment-Naïve Myelofibrosis Initiated in June 2023 – NEWTON, Mass., July 17, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (KPTI), a ...

-- Total Revenue of $157.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $120.4 Million for Full Year 2022, Meeting Company's Guidance -- -- Updated Results from the Phase 1 Study of ...

KARYOPHARM THERAPEUTICS ($KPTI) posted quarterly earnings results on Wednesday, February 19th. The company reported earnings of -$0.24 per share, beating estimates of ...

Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced the presentation of updated exploratory subgroup analyses from the SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial ...

Richard Paulson, President and CEO, highlighted a "very productive quarter for Karyopharm, one defined by meaningful clinical progress and strengthened financial flexibility that together set the ...